You are here

  • Home
  • Archive
  • Volume 5, Issue 6
  • Doxazosin was associated with more stroke and cardiovascular disease events than chlorthalidone in high risk hypertension

Article Text

Article menu
Download PDFPDF
Therapeutics
Doxazosin was associated with more stroke and cardiovascular disease events than chlorthalidone in high risk hypertension

https://doi.org/10.1136/ebm.5.6.172

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    (2000) JAMA 283, 1967. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).. Apr 19;. :. –75.
    OpenUrlCrossRefPubMedWeb of Science

    
 
 QUESTION: In high risk hypertensive patients, is doxazosin (an α-adrenergic blocker) or chlorthalidone (a diuretic) more effective in reducing cardiovascular disease (CVD) events?

    Design

    Randomised (allocation concealed*), blinded (clinicians and patients),* controlled trial with median 3.3 year follow up.

    Setting

    625 centres in the US and Canada.

    Patients

    24 335 patients who were ≥55 years of age (mean age 67 y, 53% men, 49% white non-Hispanic), had systolic blood pressure (BP) ≥140 mm Hg or diastolic BP ≥90 mm Hg, took medication for hypertension, and had ≥1 other risk factor for coronary heart disease (CHD). {Exclusion criteria included myocardial infarction (MI), stroke, or angina pectoris in the past 6 months; congestive heart failure (CHF) or ejection fraction <35%; or serum creatinine concentration ≥177 μmol/l.}† 97% of patients were included in the analysis.

    Intervention

    Patients were allocated …

    View Full Text

    Footnotes

    • Sources of funding: National Heart, Lung, and Blood Institute and Pfizer. Medication supplied by Pfizer Inc, AstraZeneca, and Bristol-Myers Squibb.

    • For correspondence: Dr B R Davis, University of Texas-Houston, School of Public Health, 1200 Herman Pressler Street, Houston, TX 77030, USA. Fax +1 713 500 9530.

    • ↵* See glossary.

    • ↵† Davis BR, Cutler JA, Gordon DJ, et al. Am J Hypertens 1996;9:342–60.